334 related articles for article (PubMed ID: 23722540)
1. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.
Dangaj D; Lanitis E; Zhao A; Joshi S; Cheng Y; Sandaltzopoulos R; Ra HJ; Danet-Desnoyers G; Powell DJ; Scholler N
Cancer Res; 2013 Aug; 73(15):4820-9. PubMed ID: 23722540
[TBL] [Abstract][Full Text] [Related]
2. Isolation and Validation of Anti-B7-H4 scFvs from an Ovarian Cancer scFv Yeast-Display Library.
Dangaj D; Scholler N
Methods Mol Biol; 2015; 1319():37-49. PubMed ID: 26060068
[TBL] [Abstract][Full Text] [Related]
3. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells.
Miao G; Sun X
Biomed Pharmacother; 2021 Sep; 141():111913. PubMed ID: 34328096
[TBL] [Abstract][Full Text] [Related]
5. Construction, expression and functional analysis of anti-B7-H4- scFv-CH3 recombinant antibody.
Ji H; Guo J; Yang Y; Xu C; Mao W
J Biosci; 2018 Sep; 43(4):661-671. PubMed ID: 30207312
[TBL] [Abstract][Full Text] [Related]
6. Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: a potential mechanism of immune escape.
Chen C; Qu QX; Shen Y; Mu CY; Zhu YB; Zhang XG; Huang JA
Cancer Lett; 2012 Apr; 317(1):99-105. PubMed ID: 22108530
[TBL] [Abstract][Full Text] [Related]
7. Potential targeting of B7-H4 for the treatment of cancer.
Podojil JR; Miller SD
Immunol Rev; 2017 Mar; 276(1):40-51. PubMed ID: 28258701
[TBL] [Abstract][Full Text] [Related]
8. Generation of avian-derived anti-B7-H4 antibodies exerts a blockade effect on the immunosuppressive response.
Lin TY; Tsai TH; Chen CT; Yang TW; Chang FL; Lo YN; Chung TS; Cheng MH; Chen WC; Tsai KC; Lee YC
Exp Anim; 2021 Aug; 70(3):333-343. PubMed ID: 33716253
[TBL] [Abstract][Full Text] [Related]
9. Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model.
Leung J; Suh WK
J Immunol; 2013 Jun; 190(12):6651-61. PubMed ID: 23686485
[TBL] [Abstract][Full Text] [Related]
10. Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.
Smith JB; Lanitis E; Dangaj D; Buza E; Poussin M; Stashwick C; Scholler N; Powell DJ
Mol Ther; 2016 Nov; 24(11):1987-1999. PubMed ID: 27439899
[TBL] [Abstract][Full Text] [Related]
11. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.
Kryczek I; Zou L; Rodriguez P; Zhu G; Wei S; Mottram P; Brumlik M; Cheng P; Curiel T; Myers L; Lackner A; Alvarez X; Ochoa A; Chen L; Zou W
J Exp Med; 2006 Apr; 203(4):871-81. PubMed ID: 16606666
[TBL] [Abstract][Full Text] [Related]
12. [Construction of anti-B7-H4-scFv library and screening and identification of anti-B7-H4-scFv].
Shao L; Xu C; Ji H; Mao W; Wang Y; Liu X; Zhu Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2016 Sep; 32(9):1260-6. PubMed ID: 27609584
[TBL] [Abstract][Full Text] [Related]
13. B7-H4 is Inversely Correlated With T-Cell Infiltration in Clear Cell but Not Serous or Endometrioid Ovarian Cancer.
Pagnotti GM; Atkinson RM; Romeiser J; Akalin A; Korman MB; Shroyer KR
Appl Immunohistochem Mol Morphol; 2019 Aug; 27(7):515-522. PubMed ID: 29189263
[TBL] [Abstract][Full Text] [Related]
14. Novel B7-H4-mediated crosstalk between human non-Hodgkin lymphoma cells and tumor-associated macrophages leads to immune evasion via secretion of IL-6 and IL-10.
Che F; Heng X; Zhang H; Su Q; Zhang B; Chen Y; Zhang Z; Du Y; Wang L
Cancer Immunol Immunother; 2017 Jun; 66(6):717-729. PubMed ID: 28246881
[TBL] [Abstract][Full Text] [Related]
15. B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look.
Smith JB; Stashwick C; Powell DJ
Gynecol Oncol; 2014 Jul; 134(1):181-189. PubMed ID: 24657487
[TBL] [Abstract][Full Text] [Related]
16. B7-H4, a promising target for immunotherapy.
Wang JY; Wang WP
Cell Immunol; 2020 Jan; 347():104008. PubMed ID: 31733822
[TBL] [Abstract][Full Text] [Related]
17. A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 Expression.
Gitto SB; Whicker M; Davies G; Kumar S; Kinneer K; Xu H; Lewis A; Mamidi S; Medvedev S; Kim H; Anderton J; Tang EJ; Ferman B; Coats S; Wilkinson RW; Brown E; Powell DJ; Simpkins F
Clin Cancer Res; 2024 Apr; 30(8):1567-1581. PubMed ID: 37882675
[TBL] [Abstract][Full Text] [Related]
18. Host b7x promotes pulmonary metastasis of breast cancer.
Abadi YM; Jeon H; Ohaegbulam KC; Scandiuzzi L; Ghosh K; Hofmeyer KA; Lee JS; Ray A; Gravekamp C; Zang X
J Immunol; 2013 Apr; 190(7):3806-14. PubMed ID: 23455497
[TBL] [Abstract][Full Text] [Related]
19. Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target.
MacGregor HL; Ohashi PS
Clin Cancer Res; 2017 Jun; 23(12):2934-2941. PubMed ID: 28325750
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model.
Leung J; St-Onge P; Stagg J; Suh WK
Cancer Immunol Immunother; 2017 Apr; 66(4):491-502. PubMed ID: 28074226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
